In BC, the clinical analysis showed that NLRP3 and PYCARD expressions were strongly associated with more aggressive clinicopathological factors such as tumor size and proliferative index Ki67 and contributed to BC progression, especially in luminal BC patients [61]. This evidence concerns the gene MKI67 and breast cancer.